A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
Could tweaking methodologies improve amyloid diagnosis and tracking?
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.